Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
0(0%)
Results Posted
8%(1 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_3
4
27%
Ph phase_2
2
13%
Ph phase_1
9
60%

Phase Distribution

9

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
9(60.0%)
Phase 2Efficacy & side effects
2(13.3%)
Phase 3Large-scale testing
4(26.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(12)
Terminated(2)
Other(1)

Detailed Status

Completed12
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (60.0%)
Phase 22 (13.3%)
Phase 34 (26.7%)

Trials by Status

unknown17%
terminated213%
completed1280%

Recent Activity

0 active trials
Showing 5 of 15
terminatedphase_2

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

NCT01367275
completedphase_3

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

NCT00908752
completedphase_3

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

NCT00825955
unknownphase_1

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

NCT03895788
completedphase_3

First Line Hepato Cellular Carcinoma (HCC)

NCT00858871
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT01367275Phase 2

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Terminated
NCT00908752Phase 3

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Completed
NCT00825955Phase 3

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Completed
NCT03895788Phase 1

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Unknown
NCT00858871Phase 3

First Line Hepato Cellular Carcinoma (HCC)

Completed
NCT00594984Phase 1

Phase I/II Combination With Irinotecan- Erbitux

Completed
NCT01108705Phase 3

Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment

Terminated
NCT00633789Phase 2

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Completed
NCT01046864Phase 1

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Completed
NCT01540461Phase 1

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Completed
NCT00437437Phase 1

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Completed
NCT00437424Phase 1

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Completed
NCT00390936Phase 1

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Completed
NCT00435669Phase 1

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Completed
NCT00207103Phase 1

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15